Abstract
This article briefly discusses nonalcoholic fatty liver disease (NAFLD) and its association with the metabolic syndrome, its pathogenesis and natural history. It then presents a detailed discussion on the efficacy and safety of different insulin sensitizers in patients who have NASH.
Original language | English (US) |
---|---|
Pages (from-to) | 1067-1087 |
Number of pages | 21 |
Journal | Endocrinology and metabolism clinics of North America |
Volume | 36 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2007 |
Externally published | Yes |
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology